Bioprinting is rapidly moving from research labs into commercial reality, and it is reshaping how the pharmaceutical and ...

Companies are facing a situation where they need to fill their pipelines, but also navigate a competitive environment for the best assets.

T he biotech and pharmaceutical sectors stand at the brink of innovation and strategic transformation. Market momentum continues to build, with the global biotechnology market valued at around $2 ...

MATAWAN, N.J.--(BUSINESS WIRE)-- Apimeds Pharmaceuticals US, Inc. (APUS) (“Apimeds”) today announced the expansion of its ai² Future Labs program by engaging graduate students from the University of ...

The sheer growth of small biotechs and mid‑sized pharma companies entering the field has reshaped expectations of Contract Development and Manufacturing Organisations (CDMOs).

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

MATAWAN, N.J.--(BUSINESS WIRE)-- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds”) today announced the launch of its ai² Future Labs program in partnership with The University of ...

The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention. The industry has recovered from a challenging 2024 and is ...